9 completed, 7 unknown, 2 recruiting, 1 active not recruiting. 7 Phase 3, 5 Phase 2, 3 Not applicable, 3 Phase 1, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Unknown 4, Completed 3 |
| Phase 2 | 5 | Unknown 3, Active not recruiting 1, Recruiting 1 |
| Not applicable | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
Follow T: new trials by email Literature Review of T trials Research Report on T
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability Test Drug (Eutropin Catridge, 48IU/Cartridge), Reference Drug (Eutropin, 4 IU/vial) - Healthy Volunteers | Phase 1 | Completed | LG Chem | 48 | 2025-01-13 | 2025-04-17 |
| Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families Digital Tutorial overview, Digital Tutorial plus training Materials, Digital Tutorial plus training Materials plus feedback and Coaching - Community Reinforcement And Family Training, Family Health | Not applicable | Recruiting | We The Village, Inc. | 240 | 2024-11-04 | 2024-11-12 |
| Ultrasound Guided Fluid Loading Before Spinal Anesthesia C, T - Cesarean Section Complications, Spinal Anesthesia | Phase 4 | Completed | University Tunis El Manar | 116 | 2024-05-01 | 2025-08-07 |
| Study of Felzartamab in Healthy Adult Subjects T, R - Healthy | Phase 1 | Completed | TJ Biopharma Co., Ltd. | 24 | 2024-03-27 | 2025-08-28 |
| Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study Teniposide, Etoposide, serplulimab - Small-cell Lung Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 90 | 2024-02-01 | 2026-05-13 |
| Scalable Digital Delivery of Evidence-based Training for Professionals to Maximize Treatment Rates of OUD in Families Behavioral: Digital Tutorial Overview, Behavioral: Training Materials, Behavioral: Feedback and Coaching - Community Reinforcement And Family Training, Family Health | Not applicable | Completed | We The Village, Inc. | 47 | 2023-05-23 | 2025-01-20 |
| Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer Paclitaxel, Trastuzumab, Docetaxel - HER2-positive Breast Cancer, Adjuvant Therapy | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 190 | 2022-01-31 | 2022-01-12 |
| Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer Pyrotinib, Trastuzumab, Pertuzumab - Breast Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2021-06-03 | 2021-06-04 |
| Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer Pyrotinib, Epirubicin, Doxorubicin Hydrochloride Liposome Injection - Breast Cancer, Hormone-receptor Positive Breast Cancer | Phase 2 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 140 | 2021-04-20 | 2026-01-06 |
| Effect of Amnion Membrane With and Without Taurine on GCF TNF α Level. Scaling and root planing, Amnion membrane, Taurine - Periodontitis | Not applicable | Completed | Maharishi Markendeswar University (Deemed to be University) | 45 | 2020-12-01 | 2021-03-16 |
| Starting a Testosterone and Exercise Program After Hip Injury Testosterone, Placebo gel, Supervised exercise training - Hip Fracture, Frailty | Phase 3 | Completed | Washington University School of Medicine | 129 | 2019-03-05 | 2025-02-04 |
| Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337 T, R - Hyperlipidemias | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 45 | 2018-09-05 | 2019-01-07 |
| Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients Pegylated liposomal doxorubicin, Cyclophosphamide, Epirubicin - Breast Cancer | Phase 4 | Unknown | Zhejiang University | 384 | 2016-12-01 | 2019-04-10 |
| Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma Docetaxel, Cisplatin 1, Xeloda - Nasopharyngeal Carcinoma | Phase 3 | Unknown | Sun Yat-sen University | 235 | 2016-08-01 | 2016-06-01 |
| PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer NVB, EPI, DDP - Breast Cancer Model, Effects of Chemotherapy | Phase 3 | Unknown | Shi Yanxia | 320 | 2016-04-01 | 2017-01-16 |
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma Cisplatin 2, Docetaxel, Cisplatin 1 - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 130 | 2016-01-01 | 2016-05-26 |
| Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma Cisplatin 1, Cisplatin 2, Docetaxel - Nasopharyngeal Carcinoma | Phase 3 | Unknown | Sun Yat-sen University | 534 | 2016-01-01 | 2015-12-04 |
| A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer bevacizumab, docetaxel, doxorubicin - Breast Cancer | Phase 3 | Completed | NSABP Foundation Inc | 1613 | 2009-05-01 | 2022-04-20 |
| Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Cyclophosphamide, Docetaxel, Gemcitabine - Breast Cancer | Phase 3 | Completed | NSABP Foundation Inc | 4894 | 2004-10-01 | 2018-01-11 |
Breast Neoplasms (6) · Nasopharyngeal Carcinoma (3) · Substance-Related Disorders (2) · Adenocarcinoma (1) · Breast Diseases (1) · Carcinoma (1) · Frailty (1) · Hip Fractures (1) · Hyperlipidemias (1) · Hypotension (1) · Hypovolemia (1) · Periodontitis (1) · Sarcopenia (1) · Small Cell Lung Carcinoma (1)
Sun Yat-sen University (4) · NSABP Foundation Inc (2) · We The Village, Inc. (2) · Chong Kun Dang Pharmaceutical (1) · LG Chem (1) · Maharishi Markendeswar University (Deemed to be University) (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shi Yanxia (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · TJ Biopharma Co., Ltd. (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University Tunis El Manar (1) · Washington University School of Medicine (1) · Zhejiang University (1)
China (10) · United States (5) · South Korea (2) · India (1) · Ireland (1) · Tunisia (1)
Fang-Yun Xie, M.D. (2) · Norman Wolmark, MD (2) · Ellen F Binder, MD (1) · Erwei Song, MD.,Phd. (1) · Huang Jian, Dr (1) · Jane Macky, MA (1) · Jay Magaziner, PhD (1) · Kenneth B Schechtman, PhD (1) · Tao Pan (1) · Wenfeng Fang (1) · Xiaojiao Li, Doctor (1) · Xiaoming Zha, MD (1) · YanXia Shi, doctor (1)
PMID 23940225, PMID 36070134, PMID 38335467, PMID 40372752, PMID 41529542, PMID 41624165, PMID 42284931
R44DA053845 (2), U10CA012027 (1)